MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. This amendment was developed to complete administrative and operational refinements in advance of study initiation. Amendment 4, Version 1 updates the previously cleared smoking-only protocol (A3V1) and was… Continue reading MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
External link. We are not responsible for the content.
Read more ↗More From MAPS
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
Protected: 2026 Second Quarter — Policy & Advocacy Wrap Up
There is no excerpt because this is a protected post.
Protected: MAPS Publishes Ibogaine Investigator’s Brochure as a Free, Open-Access Resource
There is no excerpt because this is a protected post.
Latest News
Altered ‘state’ vs Altered ‘sense of self’
Psychedelic culture has given us a powerful image of transformation: the self dissolves, the familiar world disappear...
What’s the difference between recreational and therapeutic psychedelic use? 5 Questions with experimental psychologist Harriet de Wit
De Wit discusses the difficulty of finding out what a drug does, outside of its context.
World Ayahuasca Forum Brings Ancestral Intelligence to Spain
PLUS, an interview with an iconic Grateful Dead artist, ayahuasca and loneliness, and Puerto Rico's executive order. ...
Citizen Science x Phenomenology
Journaling, editing, reflecting, integrating – all remain valid when formalising your anecdotal report, to make sense...
The Psychedelic Future We Were Promised
This Week's Sunday Insider: Why the Psychedelic Future Never Arrived.
Weekly Psychedelic Policy Briefing – August 14, 2026
The FDA has finalized guidance on clinical investigations into psychedelic-assisted therapies and contract research o...